Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease.

The failure of aducanumab won’t be the final nail in the coffin of the β amyloid hypothesis, but it certainly sends a clarion call for investment in other mechanisms. The good news is that compounds against newer mechanisms are trickling into the clinic, and more lie behind them in preclinical studies. ...